Human fatty acid synthase (hFAS) is a homodimeric multidomain enzyme that catalyzes a series of reactions leading to the de novo biosynthesis of long-chain fatty acids, mainly palmitate. The carboxy-terminal thioesterase (TE) domain determines the length of the fatty acyl chain and its ultimate release by hydrolysis. Because of the upregulation of hFAS in a variety of cancers, it is a target for antiproliferative agent development. Dietary long-chain polyunsaturated fatty acids (PUFAs) have been known to confer beneficial effects on many diseases and health conditions, including cancers, inflammations, diabetes, and heart diseases, but the precise molecular mechanisms involved have not been elucidated. We report the 1.48 Å crystal structure of the hFAS TE domain covalently modified and inactivated by methyl γ-linolenylfluorophosphonate. Whereas the structure confirmed the phosphorylation by the phosphonate head group of the active site serine, it also unexpectedly revealed the binding of the 18-carbon polyunsaturated γ-linolenyl tail in a long groove-tunnel site, which itself is formed mainly by the emergence of an α helix (the "helix flap"). We then found inhibition of the TE domain activity by the PUFA dihomo-γ-linolenic acid; γ-and α-linolenic acids, two popular dietary PUFAs, were less effective. Dihomo-γ-linolenic acid also inhibited fatty acid biosynthesis in 3T3-L1 preadipocytes and selective human breast cancer cell lines, including SKBR3 and MDAMB231. In addition to revealing a novel mechanism for the molecular recognition of a polyunsaturated fatty acyl chain, our results offer a new framework for developing potent FAS inhibitors as therapeutics against cancers and other diseases.
F atty acids, the main constituents of fat, biological membrane lipids, energy storage, and signal transducer compounds, are absorbed from diet or synthesized de novo from acetyl-CoA, malonyl-CoA, and NADPH through multiple rounds of a series of reactions catalyzed by the homodimeric large multifunctional fatty acid synthase (FAS) (1) . The reactions are carried out by seven different catalytic domains in one catalytic center. The thioesterase (TE) domain, which is located at the carboxyl end of the subunit, plays critical dual roles in regulating the length of the fatty acyl chains (C14∶0, C16∶0, C18∶0), with the palmitoyl (C16∶0) being optimal, and in finally hydrolyzing the acyl-S-phosphopantetheine thioester bound to the preceding acyl-carrier protein domain to release the fatty acid.
FAS has been shown to be associated with a variety of human diseases and adverse health conditions such as obesity, cardiovascular disease, inflammation, and cancer. Its relationship with cancer pathogenesis has attracted the most attention (reviewed in refs. 2 and 3). In most normal human tissues, FAS expression is very low, but it is aberrantly elevated in a variety of cancers, including carcinoma of the prostate, breast, ovary, colon, endometrium, thyroid and skin. The elevated FAS protein expression level is also correlated with an increase in de novo fatty acid synthesis in corresponding tissues. The coupling of FAS expression with tumor progression led to the notion that FAS protein is associated with the growth and survival of cancer cells. Moreover, the identification of the oncogenic antigen-519 (OA-519) from human breast carcinoma cells as FAS has made it an important diagnostic and prognostic marker for breast cancer patients (4, 5) . The importance of FAS in cancer cells is further underscored by the observation that inhibitions of FAS catalytic activities are selectively cytotoxic to human cancer cells (reviewed in ref. 6 ). These include inhibitions of the activities of the following catalytic domains: ketoacyl synthase by cerulenin (7, 8) , C75 (9) , and epigallocatechin-3-gallate (a green tea component) (10) ; enoyl reductase by triclosan, a widely used antibacterial in soaps, mouthwashes, etc. (11) ; and thioesterase by Orlistat, an antiobesity drug approved by the Food and Drug Administration (12) . Taken together, these observations continue to make FAS an attractive target for developing unique antitumor compounds.
Long-chain polyunsaturated fatty acids (PUFAs) are essential dietary fatty acids, mainly supplied by vegetables and fishes. They have been shown to have beneficial effects on human health, such as improved heart disease-related outcomes, antiproliferative effects on tumor cells, and anti-inflammatory properties. Like the association of FAS with cancer pathogenesis, the antiproliferative effect of PUFAs, especially those belonging to the (n-3) or ω-3 and (n-6) or ω-3 series, has attracted considerable attention (reviewed in ref. 13) . Because the literature on the beneficial effects of PUFAs is vast and continues to be debated and discussed, we summarize briefly those studies that may be relevant to our structural and biochemical studies of the effects of PUFAs, especially in conjunction with FAS.
Several studies have shown that dietary PUFAs and synthetic PUFAs, particularly γ-linolenic acid (GLA, 18∶3n-6) and α-linolenic acid (ALA, 18∶3n-3) (see Scheme S1), suppress hepatic lipogenesis as compared with saturated and monounsaturated fatty acids, and that this suppression is accompanied by the inhibition of the hepatic synthesis of FAS (14) (15) (16) . (Synthetic PUFAs used in these experiments are often esterified to enhance cell uptake and then presumably hydrolyzed by lipases to their active free acid form.) GLA and ALA also selectively kill cancer cells while causing little or no harm to normal cells (17) . Exogenous supplementation with high concentrations of the methyl esters of Author contributions: W.Z., B.C., F.Z., S.J.W., and F.A.Q. designed research; W.Z., B.C., F.Z., Z.G., H.W., and J.M. performed research; W.Z., B.C., F.Z., Z.G., H.W., J.M., S.J.W., and F.A.Q. analyzed data; and F.A.Q. wrote the paper.
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GLA and ALA has also been demonstrated to significantly suppress FAS activity and expression in tumor cells (18) . Additionally, both PUFAs have been indicated to suppress overexpression of Her2/neu oncogene (19) . Finally, PUFAs have been shown to enhance the cytotoxic activity of several anticancer drugs (e.g., taxol, paclitaxel) in cell culture and in tumor-bearing mice (13) .
In mammals, including man, dihomo-γ-linolenic acid (DGLA) is metabolized from linoleic acid via GLA and further converted to arachidonic acid (AA), but because of the poor conversion efficiency, DGLA, not AA, accumulates after GLA supplementation (20) . Moreover, it has been shown recently that administration of exogenous DGLA oil (in the form of triglyceride) in rats is more effective than GLA administration for increasing the DGLA concentration within the body (21) .
The precise molecular mechanism(s) by which long-chain PUFAs exert their beneficial effects in a variety of chronic disease states, especially cancers, are not completely understood. The same is true for the mode of action(s) of PUFAs on FAS activity. A popular but controversial view is that the cytotoxic and antiproliferative effects of exogenous GLA or ALA are due to formation of peroxidation products that could then inhibit FAS (13, 22) . On the other hand, experimental data showed that PUFAs themselves are responsible for FAS suppression (23) . To further our molecular understanding of these issues, we carried out structural and biochemical studies of the 32 kDa TE domain of hFAS covalently modified by a methylfluorophosphonate head group linked to a γ-linolenyl acyl tail and, prompted by the results, investigated the inhibitions of related PUFAs on the TE activity, fatty acid biosynthesis in 3T3-L1 preadipocytes and human breast cancer cell lines.
Results
Crystal Structure of the TE Domain of hFAS with a Covalently Bound Methyl γ-Linolenylphosphonate. Long-chain polyunsaturated fatty acyl fluorophosphonates have been demonstrated previously to irreversibly inactivate phospholipases through rapid phosphorylation of a reactive serine residue in the active site (24, 25) . Our studies reported here were set in motion by the determination of the X-ray structure of the hFAS TE domain treated with twofold excess of methyl γ-linolenyl fluorophosphonate (MGLFP; Scheme S1) (see Methods and SI Methods). (Unless further specified, henceforth the FAS and its TE domain described in our work are those of hFAS.) The structure was determined by molecular replacement technique, using the ligand-free TE domain structure (26) as the search model, and refined at 1.48 Å resolution to final R-cryst and R-free values of 19.37% and 22.89%, respectively, and excellent geometry (Table S1 ). The resolution is a considerable improvement over those of previous FAS TE domain structures in the ligand-free form (2.6 Å resolution) (26) and in complex with the inhibitor Orlistat (2.3 Å resolution) (27) .
Four prominent features of the binding of MGLFP, whose well-defined electron density is shown in Fig. 1A , are as follows. First, a covalent bond is formed between the phosphorus atom of the methylphosphonate head group and the hydroxyl side chain of Ser 2308, one of the catalytic triad of residues in TE (26), yielding a methyl γ-linolenylphosphonate (MGLP) adduct ( Fig. 1 B and C). This finding is reflected by the result of thioesterase activity measurement, performed following the structure determination, showing essentially complete loss of activity after treatment of TE in solution with fourfold excess of MGLFP (e.g., see Table 1 ). Second, the γ-linolenyl (18-carbon) acyl chain is nestled and significantly buried (approximately 75% of its accessible surface area) in a long contiguous groove and tunnel (Fig. 1C) . Approximately the first eight carbons of the γ-linolenyl chain reside in the groove, and the remaining 10 carbons occupy the entire length of the tunnel. Third, ligand binding causes the emergence of an amphiphatic α-helix (residues 2342-2355), called the "helix flap" or "gatekeeper helix," which forms the major wall of, is contoured at 0.8σ above the mean density. The α-helix (the helix flap or gatekeeper helix) colored in red and adjacent to the MGLP density is composed of residues 2342-2355. The TE domain structure is made up of two subdomains-a much larger subdomain with the α/β hydrolase fold (Right) and a smaller subdomain with an all α-helices motif (α5-α8) (Left) (26) . Because the helix flap, which is missing in the first TE domain structure, precedes α5-helix, it is also identified as α5′ to preserve the original secondary structure identification. Renumbering all the helices in the TE-MGLP structure makes α5′ equivalent to α5, α5-α6, etc. and, consequently, gives rise to, the groove-tunnel site ( Fig. 1 A  and C) . Spanning the two TE subdomains (Fig. 1C) , the welldefined groove-tunnel commences near Ser 2308 in the large subdomain and terminates deep in the tunnel in the small subdomain formed by the triangulation of three helices-the helix flap, α5 (which follows the helix flap) and α8 (Fig. 1A) . This finding underscores a unique and important role of the two subdomains combined. Fourth, a total of 73 contacts (<4 Å distances) are made between MGLP and 16 TE residues (Fig. 1B) . Indicative of high complementarity, the majority of the contacts (44 total) are between the γ-linolenyl chain and nonpolar TE groups; 16 contacts were made with residues deployed by the helix flap. The other contacts were made with residues from the N terminus of α5 helix and the middle of α8 helix.
The long groove-tunnel, formed almost solely by the appearance of the gatekeeper helix, has heretofore not been observed in any previous structure of TE, either in a natural form or as an isolated domain. The critical α helix could have arisen by a γ-linolenyl chain-facilitated formation of the helix from a disordered polypeptide segment or a stabilization of a very flexible α helix. (Secondary structure predication indicated a low-probability α helix for the segment.) Because the ordered helix is approximately 10 Å to the nearest TE domain molecule in the crystal lattice, its appearance is unlikely influenced by crystal packing.
With no electron density for the segment of residues 2342-2355 in the structure of the ligand-free TE domain (26) , the groove-tunnel is not obvious. Nevertheless, the ligand-free structure has, as noted previously, a separate groove-distal pocket site (identified as Site 1) formed between the two TE subdomains (26) . Site 1 is still present in the TE-MGLP structure, together with the groove-tunnel site (named Site 2) (Fig. 1C) . The existence of Site 1, but not Site 2, in the ligand-free structure has been corroborated by computational analysis (28) (see also Fig. S1A , demonstrating a very similar result). A similar analysis of the TE-MGLP structure indicates Site 2 as the major site, exhibiting a cluster volume and energy significantly more favorable than Site 1 (Fig. S1B) . Although a site-directed mutagenesis experiment suggested possible involvement of Site 1 in the activity of the TE domain (26) and computational studies indicated docking of fatty acids to the site (28), the functional significance of the site remains to be further clarified or explored.
PUFA Inhibitions of the Thioesterase Activity of the TE Domain.
Although dietary PUFAs have long been known to provide a variety of beneficial effects on human health, the precise molecular mechanism(s) by which they exert these effects, and their specific enzyme/protein target(s), remain unclear. Our structural work, demonstrating the precise binding of the γ-linolenyl tail of MGLP to the TE domain, may have uncovered a potential molecular target, and thus, a unique mechanism of action of PUFAs. To further test these ideas, we examined the effects of related ω or (n-6) linolenic acids (GLA, DGLA, and ALA) (see Scheme S1) on the TE domain esterase activity with palmitoyl-CoA as the substrate (see SI Methods). Like MGLFP and MGLP, DGLA, ALA, and GLA have an identical set of three cis double bonds, although its location differs relative to the fatty acid chain length (Scheme S1). At a concentration of 16 μM in the assay mixture, DGLA caused about 54% reduction in activity, but ALA and GLA produced only 16% inhibition (Table 1) . DGLA acts as a competitive inhibitor, with a K i value of 6.36 μM (Fig. S2). [High substrate concentrations cause substrate or product inhibition (Fig. S2) , which may explain the observation that palmitate inhibits TE activity comparable to that by DGLA.] Esterification of DGLA (as in the compound dihomo-γ-linolenic acid ethyl ester) abolished inhibition of the TE domain activity. DGLA is less effective in inhibiting intact hFAS, causing only 31% inhibition. Phenylmethanesulfonyl fluoride (PMSF), a general reagent for rapid covalent modification of active site OH or SH groups, also caused almost complete loss of TE domain activity (Table 1 ). In the study of Menendez et al. (18) , PMSF was used in the extraction of FAS from human breast SKBR3 cancer cells treated with high concentrations of methyl ester of GLA and ALA (18) [as high as approximately 11 times the DGLA concentration used in our studies (Table 1) ], and may therefore have prevented a more accurate determination of the reduced activity of FAS from extracts of cells treated with PUFAs.
The TE-DGLA complex has resisted crystallization, despite exhaustive attempts. To get an idea of the possible mode of binding of DGLA, we carried out a straightforward modeling experiment, because DGLA more closely aligns with MGLP (Scheme S1). The C 3 -C 20 acyl segment of DGLA can be matched exactly with the entire 18-carbon γ-linolenyl tail of MGLP (Fig. S3A ). The C 2 C 1 OO − head group can be accommodated with no bad contacts in the area occupied by the methylphosphonate, which deploys hydrophobic residues (Fig. 1B) and, with slight torsional rotation, its two carboxylate oxygens positioned within hydrogen-bonding distances to the His 2481 and Ser 2308 residues of the catalytic triad (Fig S3 A and B) .
Effects of DGLA on Palmitate Biosynthesis in 3T3-L1 Preadipocytes and
on Breast Cancer Cell Lines. To test whether DGLA has an effect on de novo palmitate biosynthesis, 3T3-L1 preadipocyte cells were *Several of the abbreviations in parentheses correspond to those shown in Scheme S1. PMSF, phenylmethanesulfonylfluoride. All fatty acids were obtained from Cayman Chemicals, stored at −80°C and used from freshly made solutions in ethanol or DMSO. After obtaining the requisite aliquot, each vial of PUFA was purged with nitrogen before storage. † Concentrations refer to those in the assay mixture. ‡ Nanomoles product formed/min/mg of enzyme (see SI Methods). Average value from three assays. All assays contained about 0.8% ethanol, which only caused about <10% reduction in activity of TE in the absence of solvent.
incubated for 24 h with 20 μM DGLA. Eight hours into the incubation, [ 13 C]-sodium acetate was added. At the end of the 24-h incubation, the lipid was extracted and [ 13 C]-palmitate was analyzed by gas chromatography/mass spectrometry (GC/MS). As shown in Fig. 2A , DGLA treatment of 3T3-L1 preadipocytes reduced the [ 13 C]-acetate incorporation into [ 13 C]-palmitate by 51% (P ¼ 0.079).
We also tested the effect of the ethyl ester of DGLA on cell viability and fatty acid synthesis on some selected breast cancer cell lines. As shown in Fig. 2B , the DGLA ethyl ester impacts the viability of SKBR3 and MDAMB231 cell lines compared to noncancerous cells (HMEC) when exposed for 48 h at 20 μM concentrations. Moreover, when the breast cancer cell lines SKBR3 and MDAMB23 were exposed to the DGLA ethyl ester (20 μM) for 12 h, then treated with [ 14 C]-acetate for 6 h, the radioactivity incorporated into the fatty acid fractions (fatty acids) was 40 to 50% lower than that of the control cell lines that were not treated with the DGLA ethyl ester. The overall FAS activities in the extracts of the DGLA ethyl ester-treated cells varied, but generally were 20-40% lower than the FAS activities in the extracts of the nontreated cells.
Comparison of the Structures of TE Complexes with MGLP and Orlistat.
X-ray structure analysis has revealed two modes of binding of the inhibitor Orlistat to two independent TE domain molecules A and B (see Fig 3) in the crystal structure (27) . One mode, seen in molecule A, has a covalently bound inhibitor due to the acylation of the active site serine residue by the β-lactone ring (Fig. 3B) , and the other mode, observed in molecule B, has a noncovalently bound product owing to the hydrolysis of the β-lactone ring (Fig. 3C) . Consequently, the geometries of the three groups (palmitic core, peptidyl moiety, and hexanoyl tail) of the Orlistat differ between the two modes ( Fig. 3 A-C) .
The two TE-Orlistat and TE-MGLP complex structures are very similar; the rmsds for α-carbon atoms between different pairs of superimposed structures are 0.52 and 0.63 Å. The slight differences in the rmsds could be related to the significantly higher resolution of the TE-MGLP structure than that of the Orlistat-bound structure. Comparisons of the active site regions of the TE-MGLP and the two TE-Orlistat structures (Fig. 3) led us to the following major observations. First, the emergence of the helix flap in the active site region is, as already indicated above, unique to the TE-MGLP structure (Fig. 3 A-C) . As in the ligand-free TE domain structure (26) , the segment corresponding to the helix is disordered in the two independent structures of the TE-Orlistat complexes. Second, although the TE-Orlistat structures lack the well-defined groove-tunnel site (Site 2), they show, as in the ligand-free and TE-MGLP structures (Fig. 1C and Fig. S1A ), the presence of groove-pocket Site 1. Third, given their positions in the respective TE structures (Fig. 3 D and E) , the gatekeeper helix in the TE-MGLP complex would clash with the hexanoyl tails of the two bound Orlistats (Fig. 3 D and E) . Due to the difference in the relative orientations of the tails between the two Orlistats, the extent of the clashes would differ, with the one in the noncovalently bound inhibitor being much more severe (Fig. 3 D and E) . Fourth, major differences between the modes of binding of MGLP and the two Orlistat forms are confined to the region close to the catalytic triad (Fig. 3 D and E) . This is attributed to the differences in the chemical and conformational features between MGLP and the two forms of Orlistat. Consequently, approximately the first seven carbons of the palmitic core of Orlistat in both forms are close to the protein surface, whereas those of the γ-linolenyl acyl group of MGLP lie in the groove. Interestingly, despite the differences, the catalytic triad is nearly superimposable in the overlapped structures, attesting to the stability of the active site residues. Fifth, due to differences in binding geometries close to the catalytic triad, only the segments of approximately C 7 -C 16 of the γ-linolenyl chain of MGLP and C 8 -C 16 of the palmitic core of the covalently or noncovalently bound Orlistat are in close proximity in the superimposed structures (Fig. 3 D and E) . However, none of the carbon atoms of the γ-linolenyl chain and palmitic core superimpose, and the terminal C 17 -C 18 carbons of MGLP extend further.
Discussion
Our collective studies show two remarkable and unprecedented results: the formation of a site in a completely unlikely domain of FAS, the TE domain, with a geometry for binding a long polyunsaturated fatty acyl chain, and the inhibition of the intact homodimeric enzyme and its TE domain by a PUFA, DGLA. These results are remarkable because the TE domain has been known to act solely on long fatty acyl chains in the key terminal step of fatty acid biosynthesis. These results are also consistent with our preliminary investigation indicating that DGLA is capable of inhibiting the biosynthesis of palmitate in 3T3-L1 preadipocyte cells. Moreover, the ethyl ester of DGLA inhibits the synthesis of fatty acids in breast cancer cell lines by inhibiting FAS. It also affects the viability of these cells, as shown in Fig. 2B . The exact mechanism involved in the impact on the cells' viability is not known at this time and will be worth investigating.
The reactivity of MGLFP to the TE domain is attributed almost entirely to the phosphorylation by the phosphonate head group of the catalytic serine residue. Nevertheless, surprisingly, its γ-linolenyl chain is bound and makes excellent complementary interactions with amino acid residues in the groove-tunnel site (Site 2), which itself is formed and shaped mainly by the emergence of the helix flap (Fig. 1) . With an invisible (disordered) helix, the groove-tunnel is completely absent in the ligand-free TE structure (Fig. S1A) .
DGLA imparts greater inhibition of the thioesterase activity of the TE domain than GLA and ALA. If the DGLA modeled in the groove-tunnel site portrays its mode of binding (Fig. S3) , its specificity would be mainly governed by three factors combined: the electrostatic interactions of the carboxylate head group with the catalytic triad Ser 2308 and His 2481 residues, the placement of the three double bonds, together with the rest of the dihomo-γ-linolenyl chain to fully occupy the groove-tunnel, and the appearance of the helix flap. We infer that all three factors may be more difficult to attain by ALA or GLA. For example, if the carboxylate of ALA or GLA is made to engage in interactions identical to those of the modeled DGLA, the set of three double bonds of ALA and GLA will not superimpose with that of MGLP or the modeled DGLA, and their polyunsaturated acyl chain will fall short of extending to the end of the tunnel.
The prospect of the TE domain binding a long-chain fatty acyl group and a PUFA is very intriguing. However, whereas our studies have revealed a molecular mechanism of binding of γ-linolenyl acyl chain and by extension, DGLA, they and other previous structural analyses of the TE domain have yet to provide a more complete atomic-level understanding of how the TE domain optimally binds the palmitoyl acyl chain of the substrate or the palmitate product. Although the binding of the two palmitic cores of the Orlistats in the two TE structures differs significantly from that of the γ-linolenyl tail of MGLP (described above), owing almost solely to the formation of the groove-tunnel and its extensive involvement in interacting with the γ-linolenyl tail, Site 2 could be the site for binding the palmitoyl acyl chain or palmitate. In this scenario, binding of the acyl chain of substrates would require concomitant ordering and involvement of the helix flap in acyl chain recognition and then its subsequent release for the dissociation of the palmitate after substrate hydrolysis. How Site 2 confers fatty acyl chain specificity in this case is unclear. The proposal for palmitoyl binding in Site 2 is compounded, on the one hand, by the data showing a sharp decline in activity for fatty acyl substrates with chain lengths longer than 18 carbons (29) and, on the other hand, by the structure showing a groove-tunnel (Site 2) capable of accommodating 20-carbon-long fatty acyl chains (Figs. 1 A and C and S3A) . Interestingly, the groove-pocket Site 1 (Fig. 1C) may be more restrictive to C16 to C18 fatty acyl chains (26) .
Our results make the case for DGLA as the PUFA of choice for further or more thorough examination of its beneficial effects on a variety of chronic diseases, suppression of the transcriptional activity of the Her-2 oncogene, and synergistic amplification of anticancer drugs. Moreover, they pave the way for developing a new class of compounds to combat cancer, inflammation, or other health conditions and diseases that are linked to FAS, specifically targeting the critical TE domain. Key to drug discovery is the unique finding of the polyunsaturated fatty acyl chaininduced formation of a well-defined groove-tunnel site (Site 2) in the active site region of TE. Finally, our findings, combined with the knowledge of the presence of putative Site 1, provide a tantalizing unique avenue of approach in developing FAS TE inhibitors with greater specificity and potency.
Methods
Full methods and associated references are described in SI Methods. Protein expression and purification of the human TE domain were performed following the procedures described previously (26) . The thioesterase activity assays of FAS and its TE domain were carried out using a similar procedure, as described previously (26, 29) . The TE-MGLFP complex was prepared by mixing TE protein in a buffer solution, pH 8.0, with twofold molar excess of MGLFP, and incubating overnight in the cold room. Cocrystals were grown from 8-10 mg∕mL TE-MGLP, 18-23% PEG 3350, 0.1 M Bis-Tris buffer, pH 5.5, at room temperature by using the hanging drop method. A native dataset was collected at the SBC-19ID beamline at the Advanced Photon Source and processed on site with DENZO and SCALEPACK (30) . The structure was determined by molecular replacement using the unliganded structure as the search model (26) , and refined using the CCP4 program suite (31) . The methods for the investigations of the the effects of DGLA on palmitate biosynthesis in 3T3-L1 preadipocytes and on the viability of breast cancer cell lines are described in SI Text.
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